Markets:

Overview

News

Currencies

International

Treasuries

Sanofi - American Depositary Shares (NQ:SNY)

40.95 -0.27 (-0.67%)

Delayed Quote Updated: 12:20 PM EDT, Oct 1, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Sanofi - American Depositary Shares

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

42 43 Next >

Tiziana Life Sciences Has Only Fully Human Anti-CD3 mAB In Clinical Studies, Could Be Poised To Improve Care For Patients With Severe Multiple Sclerosis ↗

April 19, 2023

Tiziana Life Sciences (NASDAQ: TLSA), a London-based biotechnology company, is developing a first-in-class drug, Foralumab. Foralumab is the only fully human anti-CD3 monoclonal antibody (mAb) at the...

Via Benzinga

Cancer And Diabetes Remain Among The Deadliest And Most Debilitating Diseases — Is Gene Therapy The Solution? One Company, Genprex, Inc. (NASDAQ: GNPX), Thinks So ↗

April 18, 2023

On their own, cancer or diabetes can be debilitating and deadly. The two are common diseases with tremendous impact on health worldwide.

Via Benzinga

3 Healthcare Dividend Payers With Big Price Growth

April 14, 2023

Sanofi, AstraZeneca and Smith & Nephew all boast price performance better than about 80% of the broader market, and all are dividend payers.

Via MarketBeat

AbbVie Stock Shows Improved Relative Price Strength ↗

April 13, 2023

AbbVie stock had its Relative Strength Rating upgraded from 69 to 76 Thursday, but still shy of the 80 or higher score you prefer to see.

Via Investor's Business Daily

Is Sanofi Stock a Buy Now? ↗

March 25, 2023

The pharma giant has outperformed the broader market over the past 12 months.

Via The Motley Fool

Looking Into Sanofi's Recent Short Interest ↗

March 23, 2023

Via Benzinga

Sanofi (NASDAQ: SNY) Highlighted for Surprising Price Action

March 23, 2023

Via Investor Brand Network

Treatments For Non-Active Secondary Progressive Multiple Sclerosis Remain Scarce – Tiziana Life Sciences' (NASDAQ: TLSA) First-In-Class Foralumab Is Showing Promise ↗

April 12, 2023

Research is being done into whether there might be treatments that tackle Multiple Sclerosis (MS) through immunosuppression and a reduction of patient neuroinflammation. Anti-CD3 monoclonal antibodies...

Via Benzinga

Sanofi's $3B Acquisition Of Provention Bio Hits Regulatory Roadblock: FTC Requests More Information ↗

April 11, 2023

Via Benzinga

Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow ↗

April 11, 2023

A surge in oncology drug development, coupled with increased patient access and early diagnosis, has resulted in a massive increase in global spending on cancer treatments. Due to this, the global...

Via Benzinga

Zoetis Stock Shows Healthy Growth Along With Puppies, Kittens ↗

April 10, 2023

Zoetis stock is trying to complete a flat base with a 176.76 buy point. See if it can break out. Its stock got an upgrade Monday

Via Investor's Business Daily

2 Top Healthcare Stocks Defying the Bear Market ↗

April 07, 2023

The market sell-off over the past year hasn't stopped these healthcare giants from rallying.

Via The Motley Fool

Why Shares of Regeneron Are Rising Thursday ↗

March 23, 2023

Regeneron released positive phase 3 trial results for its therapy Dupixent.

Via The Motley Fool

Regeneron, Sanofi Soar On Blow-Out Results In 'Smoker's Lung' ↗

March 23, 2023

The companies' Dupixent reduced exacerbations by 30%.

Via Investor's Business Daily

Novo Nordisk Seeks to Solidify Its Lead in Diabetes Treatment and Crushing the Market ↗

April 06, 2023

Its market dominance in diabetes drugs that also help with weight loss is set to continue for at least the next few years.

Via The Motley Fool

Is This Pharma Duo on the Brink of Another Billion-Dollar Opportunity? ↗

March 30, 2023

Sanofi and Regeneron's top-selling drug could soon be approved to treat yet another disease.

Via The Motley Fool

Zoetis Stock Sees IBD Relative Strength Rating Improve To 73 ↗

March 27, 2023

Zoetis stock had its Relative Strength Rating upgraded to 73 Monday -- a nice improvement, but still shy of the 80-plus score you look for.

Via Investor's Business Daily

Sanofi, Regeneron Shares Pop On Big News About COPD Treatment

March 27, 2023

Sanofi and Regeneron bolted higher on news about their jointly developed COPD medication Dupixent. Analysts say sales may hit $20 billion within a decade.

Via MarketBeat

Could This Label Expansion Be a Growth Catalyst for Sanofi Stock? ↗

March 25, 2023

Sanofi and Regeneron's mega-blockbuster drug could soon be approved in the U.S. for yet another indication.

Via The Motley Fool

Stock Market Split As Fed Hikes Rates, Banks Keep Tumbling; Nvidia, On Holding In Focus: Weekly Review ↗

March 24, 2023

The major indexes showed volatile, divergent action.

Via Investor's Business Daily

Regeneron Pharmaceuticals Analysts React To Drug Trial Results: Why Whales Are Diving In ↗

March 24, 2023

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced the Phase 3 trial of Dupixent (dupilumab), developed with Sanofi (NASDAQ: SNY), for uncontrolled chronic obstructive pulmonary disease (COPD) met...

Via Benzinga

Regeneron Pharmaceuticals Options Traders Betting On Stock Falling This Much By April Expiration ↗

March 24, 2023

Sanofi (NASDAQ: SNY) and Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) shares surged on Thursday after the companies announced primary and all key secondary endpoints were met in a Phase 3 trial...

Via Benzinga

REGN Stock Alert: Regeneron Pharmaceuticals Gains on Dupixent Drug Data ↗

March 23, 2023

Regeneron Pharmaceuticals (REGN) stock is on the rise Thursday after the company released its latest clinical trial data on Dupixent.

Via InvestorPlace

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Oak Street Health (NYSE – OSH), Seagen Inc. (Nasdaq - SGEN), Provention Bio Inc. (Nasdaq - PRVB), Kimball International, Inc. (Nasdaq – KBAL)

March 23, 2023

From Brodsky & Smith LLC

Via GlobeNewswire

Apple Jumps Movie Production Bandwagon, Billionaire Jim Ratcliffe Bids For Manchester United, Elon Musk Seeks Funding For SpaceX From Middle-Eastern Fund: Today's Top Stories ↗

March 23, 2023

Bloomberg

Via Benzinga

Why Regeneron Pharmaceuticals And Sanofi Shares Are Trading Higher Today ↗

March 23, 2023

Sanofi-Regeneron stocks are trading higher today after their blockbuster drug aced the pivotal COPD trial.

Via Benzinga

Credit Suisse's $17B Of AT1 Debt Written Down To Zero, Richard Branson's Virgin Orbit Plans Insolvency, Court Freezes Volkswagen's Russian Assets: Today's Top Stories ↗

March 20, 2023

Reuters

Via Benzinga

Large Vaccine Players Including GSK, Moderna Prepare For Bird Flu Vaccine 'Just In Case' ↗

March 20, 2023

Via Benzinga

Dupixent® (dupilumab) Late-Breaking Data at AAD Show Significant Improvements in Signs and Symptoms of Moderate-to-severe Atopic Hand and Foot Dermatitis

March 18, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Stock Market Diverges Amid Bank Woes, Growth Gains; First Republic, Credit Suisse, Meta In Focus: Weekly Review ↗

March 17, 2023

A market rally is underway, but bank stocks kept tumbling.

Via Investor's Business Daily

< Previous 1 2

...

22 23 24 25 26 27 28 29 30

...

42 43 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.